Clinical Trials
55
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Lead Evaluation for Defibrillation and Reliability Post Approval Study
- Conditions
- Tachyarrhythmia
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-10-21
- Lead Sponsor
- Medtronic
- Target Recruit Count
- 2000
- Registration Number
- NCT07005232
- Locations
- 🇺🇸
Hartford Hosptial, Hartford, Connecticut, United States
🇺🇸Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States
🇺🇸Saint Lukes Health System, Kansas City, Missouri, United States
Product Surveillance Registry; Ear, Nose and Throat - EXTEND Cohort
- Conditions
- Chronic Rhinosinusitis (CRS)
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Medtronic
- Target Recruit Count
- 100
- Registration Number
- NCT06671561
Product Surveillance Registry; Ear, Nose &Amp; Throat - NIM Vital Cohort
- Conditions
- Intracranial SurgeryExtracranial SurgeryIntratemporal SurgeryExtratemporal SurgeryNeck SurgerySpine SurgeryThoracic SurgeryUpper Extremity SurgeryLower Extremity Surgery
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-09-24
- Lead Sponsor
- Medtronic
- Target Recruit Count
- 205
- Registration Number
- NCT06637995
- Locations
- 🇩🇪
Universitatsklinikum Halle (Saale), Halle, Germany
Enlighten Study: The EV-ICD Post Approval Registry
- Conditions
- TachycardiaVentricular Arrhythmia
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-07-30
- Lead Sponsor
- Medtronic
- Target Recruit Count
- 1000
- Registration Number
- NCT06048731
- Locations
- 🇺🇸
Cardiology Associates Medical Group, Huntington Park, California, United States
🇺🇸Sequoia Hospital, Redwood City, California, United States
🇺🇸University of California San Diego, San Diego, California, United States
Propel Drug-Eluting Sinus Stent Family
- Conditions
- Chronic Rhinosinusitis (Diagnosis)
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Medtronic
- Target Recruit Count
- 200
- Registration Number
- NCT05925985
- Locations
- 🇩🇪
Universitätsklinikum Freiburg Klinik für Hals, Nasen und Ohrenheilkunde, Freiburg, Germany
🇩🇪Katholisches Krankenhaus Hagen, Hagen, Germany
🇩🇪Städtisches Klinikum Karlsruhe GmbH, Karlsruhe, Germany
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next
News
Orchestra BioMed Initiates Pivotal Trial for Novel Sirolimus-Eluting Balloon in Coronary In-Stent Restenosis
Orchestra BioMed has enrolled the first patients in the Virtue Trial, a pivotal U.S. study comparing its novel Virtue SAB sirolimus-eluting balloon to the FDA-approved AGENT paclitaxel-coated balloon for treating coronary in-stent restenosis.
Johnson & Johnson to Spin Off $9.2 Billion Orthopedics Business as DePuy Synthes
Johnson & Johnson announced plans to spin off its orthopedics business into a standalone company called DePuy Synthes within 18-24 months, generating $9.2 billion in fiscal year 2024 sales.
RevBio Secures $2.2 Million NIH Grant to Advance TETRANITE Bone Adhesive for Vertebral Fracture Treatment
RevBio received a $2.2 million Phase II SBIR grant from the National Institute on Aging to advance preclinical testing of TETRANITE, a synthetic bone adhesive for treating vertebral compression fractures.
FDA Approves Medtronic's Altaviva Implantable Device for Urge Urinary Incontinence
The FDA approved Medtronic's Altaviva device on September 19, 2025, marking the first implantable tibial neuromodulation therapy that allows patients to return home with therapy already activated.
Medtronic's Hugo Robotic Surgery System Achieves 100% Success Rate in First U.S. Hernia Repair Study
Medtronic's Hugo robotic-assisted surgery system achieved a 100% surgical success rate in hernia repair procedures, significantly exceeding the pre-specified performance goal of 85%.
Ketryx Secures $39M Series B to Accelerate AI-Powered Compliance Platform for Life Sciences
Ketryx, an AI-powered compliance platform for life sciences companies, raised $39 million in Series B funding led by Transformation Capital to advance regulatory workflows and product development.
Medtronic Gains Japanese Approval for Symplicity Spyral Renal Denervation System to Treat Resistant Hypertension
Medtronic received approval from Japan's PMDA for its Symplicity Spyral renal denervation system to treat resistant hypertension, addressing a significant health concern affecting approximately 43 million Japanese adults.
FDA Clears Medtronic's MiniMed 780G System for Abbott Sensor Integration and Type 2 Diabetes Use
The FDA cleared Medtronic's SmartGuard algorithm as an interoperable automated glycemic controller, enabling integration with Abbott's Instinct sensor for type 1 diabetes patients.
Pharming Group Appoints Kenneth Lynard as Chief Financial Officer to Strengthen Rare Disease Growth Strategy
Pharming Group N.V. announced the appointment of Kenneth Lynard as Chief Financial Officer, effective October 1, 2025, following strong first half 2025 financial results.
ALONE-AF Trial Shows Discontinuing Anticoagulants After Successful AFib Ablation Reduces Bleeding Risk
The ALONE-AF trial demonstrated that discontinuing oral anticoagulant therapy one year after successful atrial fibrillation ablation resulted in significantly lower rates of stroke, systemic embolism, and major bleeding compared to continuing therapy.